Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 360

Results For "ED"

9532 News Found

WHO and OneSight EssilorLuxottica partner to expand vision care in Karnataka
Healthcare | October 09, 2025

WHO and OneSight EssilorLuxottica partner to expand vision care in Karnataka

WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030


Briefs: Panacea Biotec and Shukra Pharmaceuticals
News | October 09, 2025

Briefs: Panacea Biotec and Shukra Pharmaceuticals

Panacea Biotec receives acceptance from CMSS for supply of bOPV


Terumo India launches FineCross M3 micro-guide catheter
Medical Device | October 08, 2025

Terumo India launches FineCross M3 micro-guide catheter

FineCross M3 empowers physicians to perform safer PCI procedures, helping improve outcomes in patients with challenging coronary anatomies


Indian pharmaceutical market grows at 7.3% yoy in September 2025: Ind-Ra
News | October 08, 2025

Indian pharmaceutical market grows at 7.3% yoy in September 2025: Ind-Ra

Positive volume growth was observed in key therapies such as respiratory (13.2% yoy), anti-neoplastics (12.1% yoy) and cardiac (4.8% yoy) during September 2025


Lupin to build $250 million manufacturing facility in Florida
News | October 08, 2025

Lupin to build $250 million manufacturing facility in Florida

Furthering?U.S.-based?pharmaceutical?capacity?to?produce?critical respiratory medicines?


Biocon and Carnegie receive FDA tentative approval for Rifaximin tablets
Drug Approval | October 07, 2025

Biocon and Carnegie receive FDA tentative approval for Rifaximin tablets

Rifaximin tablets are a rifamycin antibacterial indicated for reducing the risk of overt hepatic encephalopathy


Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
Drug Approval | October 07, 2025

Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg

Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ


FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL
Drug Approval | October 07, 2025

FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL

Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older


Merck completes acquisition of Verona Pharma
News | October 07, 2025

Merck completes acquisition of Verona Pharma

Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio


IMCD unveils future of beauty at In-Cosmetics Latin America 2025
News | October 07, 2025

IMCD unveils future of beauty at In-Cosmetics Latin America 2025

IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends